Chat with us, powered by LiveChat

AstraZeneca, Novartis, Pfizer and Teva join new Lhasa Limited data sharing initiative to better understand mutagenic potential of complex nitrosamines

The data sharing initiative on structurally-complex nitrosamines is a collaborative project facilitated by Lhasa Limited, in partnership with the pharmaceutical industry.

Following a successful launch in 2021, Lhasa is delighted to announce that the project currently holds 4 respected members within the pharmaceutical industry: AstraZeneca, Novartis, Pfizer and Teva, with five additional pharmaceutical companies in the process of joining.

Partners of this initiative anonymously share Ames data on structurally-complex (e.g. API-like) nitrosamines. Data is input by Lhasa (in an anonymised form) into a shared database to enable read across and reduce duplicate testing. The project also aims to use this shared data to refine and improve structure activity relationship evaluations (SARs) for such complex nitrosamines – identifying trends in structure versus mutagenic potential.

Lhasa’s nitrosamine data sharing initiative has expanded quickly since the launch of the project in 2021 and remains open to new members. Find out more about the nitrosamine data sharing initiative on our website. Alternatively, you can enquire about joining the initiative here.